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Translational relevance 
Germline variants in cancer stem cells (CSCs) may have an important role in tumor 
recurrence despite adjuvant chemotherapy. In the present study, we investigated germline 
polymorphisms in a comprehensive panel of genes in the Wnt, Notch and Hedgehog 
pathways that have been previously investigated for their biological function and/ or 
associated with CSCs and cancer risk or clinical outcome to predict tumor recurrence in 
patients with stage II and III colon carcinoma. These common DNA-sequence variations may 
alter the gene function and/ or activity including transcription, translation or splicing, 
thereby causing inter-individual differences in relation to tumor recurrence capacity. Our 
study provides the first evidence that GLI1 rs2228226 G>C may predict early tumor 
recurrence in stage II and III colon carcinoma patients.  
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Abstract 
Purpose: Cumulating evidence indicates that germline variants in Wnt, Notch and Hedgehog 
pathways are involved in colon carcinoma progression and metastasis. We investigated 
germline polymorphisms in a comprehensive panel of Wnt, Notch and Hedgehog pathway 
genes to predict time to recurrence (TTR) and overall survival (OS) in patients with stage II 
and III colon carcinoma.  
Experimental design: A total of 742 consecutively collected patients with stage II and III 
colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 
18 germline polymorphisms in Wnt, Notch and Hedgehog pathway genes (SFRP, DKK 2 and 3, 
AXIN2, APC, MYC, TCF7L2, NOTCH2 and GLI1) by TaqMan 5'-exonuclease assays. 
Results: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226 G>C was 
significantly associated with decreased TTR in a recessive genetic model after adjustment for 
multiple testing (HR 2.35, Cl95% 1.48-3.74, p<0.001) and remained significant in multivariate 
analysis including clinical stage, lymphovascular-, vascular- and perineural-invasion (HR 2.43, 
Cl95% 1.52-3.87, p<0.001). In subanalyses, the association was limited to patients with 
surgery alone (HR 3.21, Cl95% 1.59-6.49, p=0.001), in contrast to patients with adjuvant 
chemotherapy (HR 0.82, Cl95% 0.35-1.95, p=0.657). When the subgroup of patients with 
“high-risk” GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-FU-based 
chemotherapy could be found. 
Conclusion: This is the first study identifying GLI1 rs2228226 G>C as an independent 
prognostic marker in stage II and III colon carcinoma patients. Prospective studies are 
warranted to validate our findings. 
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Introduction 
Colorectal carcinoma is the third cause of cancer-related death in the United States and the 
second cause of cancer mortality in Europe (1, 2). Across all stages, approximately 30% of 
patients with colon carcinoma develop synchronous or metachronous metastases (3). The 5-
year survival rate of colon carcinoma patients with metastatic disease is less than 10% (4). 
 
In the absence of adjuvant chemotherapy, approximately 50% of colon carcinoma patients 
with resectable disease are cured by surgery alone, whereas 50% relapse. Using adjuvant 
chemotherapy following surgery rescues approximately 15% of patients from the relapsing 
group. In current practice, the majority of these colon carcinoma patients receive adjuvant 
treatment unnecessarily, either because they were cured by surgery alone or because they 
will relapse despite adjuvant treatment. It is therefore essential to identify patients who will 
benefit from adjuvant therapy, sparing others needless toxicity and the financial burden of 
chemotherapy that will not work (5-7). Tumor recurrence after curative surgery remains a 
major obstacle for improving overall cancer survival, which may be in part due to the 
existence of cancer stem cells (CSC). Current therapies target populations of rapidly growing 
and differentiated tumor cells, but have shown to lack activity against CSCs (8, 9). CSCs 
therefore may have an important role in tumor recurrence despite adjuvant chemotherapy 
(9, 10). There is strong evidence that the embryonic signaling pathways Wnt, Notch and 
Hedgehog operate in CSCs and drive tumor progression, metastasis and chemoresistance 
(11-18). 
 
There is substantial germline genetic variability within the genes of the Wnt, Notch and 
Hedgehog pathways, including multiple single nucleotide polymorphisms (SNPs). These 
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common DNA-sequence variations may alter the gene function and/ or activity including 
transcription, translation or splicing, thereby causing inter-individual differences in relation 
to tumor recurrence capacity and chemoresistance (19-29). Furthermore, common gene 
variants may also predict chemoresistance and toxicity to 5-FU and/ or oxaliplatin as recently 
shown for the thymidylate synthetase (Ts), 5 methyltetrahydrofolate-homocysteine 
methyltransferase reductase (MTRR), multidrug resistance protein 2 (MRP2), 
dihydropyrimidine dehydrogenase (DPD) and the X-ray repair cross-complementing protein 
1 (XRCC1) genes (30-35). 
 
In the present study, we investigated 18 germline polymorphisms in a comprehensive panel 
of genes in the Wnt, Notch and Hedgehog pathways that have been previously investigated 
for their biological function and/ or associated with cancer risk or clinical outcome to predict 
tumor recurrence in patients with stage II and III colon carcinoma. This study was conducted 
adhering to the reporting recommendations for prognostic tumor marker studies (36, 37). 
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Materials and methods 
Eligible patients  
Between 1995 and 2011, 742 patients with histopathologically confirmed stage II and III 
colon carcinoma were consecutively recruited at the Division of Clinical Oncology, 
Department of Medicine, Medical University of Graz. Tissue samples from 522 patients were 
available for current genetic analyses. Tissue samples were provided by the Biobank of the 
Medical University of Graz, the Department of Pathology of the General Hospital Graz West 
and the Department of Pathology of the General Hospital Leoben. Patients treated with 
adjuvant chemotherapy received 5-FU-based regimens. All patients were included in the 
colon carcinoma surveillance program of the Division of Clinical Oncology of the Medical 
University of Graz, providing history and physical examination and CEA determination every 
3 months for 3 years and every 6 months at years 4 and 5 after surgery, colonoscopy at year 
1 and thereafter every 3-5 years and chest X-ray and abdominal ultrasound or CT scans of 
chest and abdomen every 6 months for the first 5 years and in 12 months interval in years 6-
10 after diagnosis. Patient data were collected retrospectively through chart review. This 
study has been approved by the Institutional Review Board (IRB) of the Medical University of 
Graz. All participants were Caucasians. 
 
Candidate gene polymorphisms 
Common and putatively functional Wnt, Notch and Hedgehog gene polymorphisms were 
selected using stringent and pre-defined selection criteria: (a) minor allele frequency ≥10% in 
Caucasians (based on the population genetics section in the Ensembl Genome Browser); (b) 
polymorphism that could alter the function of the gene in a biologically relevant manner 
(either published data or predicted function using Functional-Single-Nucleotide-
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Polymorphism (F-SNP) database (38, 39); (c) published clinical associations (e.g. cancer risk 
and/ or clinical outcome or chemoresistance). As it was not possible to select all Wnt, Notch 
and Hedgehog pathway gene variants matching these criteria for study power reasons, we 
focused on the most promising genes and polymorphisms. Table 1 summarizes the genes 
and polymorphisms investigated in our study cohort including location and function/ clinical 
association. 
 
Isolation of genomic DNA and determination of single nucleotide polymorphisms 
Genomic DNA was extracted from paraffin-embedded normal tissue adjacent to the tumor 
samples to obtain germline DNA. DNA isolation was performed by use of the QIAamp DNA 
mini Kit (Qiagen) and according to the manufacturer's instructions. Genotypes were centrally 
determined by 5'-exonuclease assay (TaqMan) at the Medical University of Graz. Primer and 
probe sets were designed and manufactured using Applied Biosystems ‘Assay-by-Design’ 
custom service (Applera, Austria). General TaqMan reaction conditions were according to 
the manufacturer of the assays. As a control for consistency of genotyping methods, 
determination of genotypes was repeated in at least 96 samples. The rules of good 
laboratory and clinical practice were observed. The investigator analyzing the germline 
polymorphisms was blinded to the clinical dataset.  
 
Immunohistochemistry 
Immunohistochemistry was performed on a Ventana XT immunostainer using UltraView DAB 
as the detection kit and CC1 32min as heat induced epitope retrieval (HIER). The primary 
antibody was incubated for 32 minutes each: Anti-Interleukin (IL) 17 antibody ab 
9565/Abcam in a dilution of 1:40; Anti-IL23 antibody ab115759/Abcam in a dilution of 1:50; 
Research. 
on March 25, 2015. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 27, 2014; DOI: 10.1158/1078-0432.CCR-13-1517 
 11
Anti-GLI1 (H-300) sc-20687 Santa Cruz Biotechnology, Inc. in a dilution of 1:30. The tumor 
center of the stained slides was captured with a 20x objective on a Eclipse 80i microscope 
with Digital sight DS-Fi1 digital camera and NIS-Elements D Version 3.21.04 software, Nikon, 
Japan with same correction for brightness and white balance for all images. Based on the 
images, staining intensity in the tumor cells was visually semiquantified and classified by low, 
moderate and high expression. 
 
Statistical analysis 
The endpoint of the study was time to recurrence (TTR). TTR was calculated from the date of 
diagnosis of colon cancer to the date of the first observation of tumor recurrence. TTR was 
censored at the time of death or at the last follow-up if the patient remained tumor 
recurrence free at that time. The statistical power to detect or exclude effects for the SNPs 
we investigated depended on minor allele frequency (MAF) and SNP effect size. For the 
variant with the lowest MAF, SFRP rs7775, the present study had a power of 0.98, 0.89 or 
0.70 to detect or exclude a HR of 2.0, 1.7 or 1.5 for recurrence. The statistical power 
increased with higher MAF and/ or higher HRs. The secondary end point was overall survival 
(OS). OS was defined as the time from date of diagnosis of colon cancer to death from any 
cause. Allelic distribution of the polymorphisms was tested for deviation from Hardy-
Weinberg equilibrium using HW Diagnostics-Version 1.beta (Fox Chase Cancer Center, 
Philadelphia, PA). The distribution of polymorphisms across baseline demographic, clinical 
and pathological characteristics was examined using Fisher's exact test. The association of 
clinicopathological features and polymorphisms with TTR and OS was analyzed using Kaplan-
Meier curves and log-rank test. In the multivariate Cox-regression analyses, the models were 
adjusted for significant clinicopathological features from univariate analysis of TTR and OS. 
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The true mode of inheritance of all polymorphisms tested has not been established yet and 
we evaluated a codominant, dominant or recessive genetic model where appropriate. The 
significance threshold for an overall type I error rate of 0.05 was set at p<0.003 based on a 
conservative Bonferroni correction for multiple comparison. The interactions between 
polymorphisms and adjuvant chemotherapy on TTR were tested by comparing likelihood 
ratio statistics between the baseline and nested Cox proportional hazards models that 
include the multiplicative product term. Case-wise deletion for missing polymorphisms was 
used in univariate and multivariate analyses. The association between the GLI1 rs2228226 
genotypes and GLI1, IL17 and IL21 expression in tumor was examined using chi-square test. 
All analyses have been performed using the SPSS 21.0 statistical software package (SPSS Inc., 
Sunnyvale, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
Research. 
on March 25, 2015. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 27, 2014; DOI: 10.1158/1078-0432.CCR-13-1517 
 13
Results 
The baseline characteristics of the 742 patients included in this analysis are summarized in 
Table 2. 231 patients received infusional 5-FU monotherapy, 110 patients capecitabine 
monotherapy, 108 patients FOLFOX, 16 patients XELOX and the treatment regimen of 18 
patients was unknown. The median age at time of diagnosis was 64 years (range 27-95 
years), with a median follow-up time of 64.8 months (range 1-199 months). The median TTR 
was 54.5 months (range 1-199 months) and the median OS was 64.8 months (range 1-199 
months). The genotyping quality control provided a genotype concordance of 100%. 
Genotyping was successful in at least 91% of patients for each polymorphism analyzed, with 
the exception of DKK3 rs7396187 (86.8%). In failed cases, genotyping was not successful 
because of limited quantity and/ or quality of extracted genomic DNA. The genotype 
frequencies for all polymorphisms were within the probability limits of Hardy-Weinberg 
equilibrium. 
 
In our study cohort, we found a significant association between tumor size, lymph node 
involvement, lymphovascular-, vascular- and perineural-invasion and clinical stage with TTR 
and OS. Additionally, tumor location and histopathological grade were significantly 
associated with OS (Table 2). When the polymorphisms were correlated with the 
clinicopathological features, we found a significant association between APC rs454886 G>A 
and tumor size (p=0.001) and vascular invasion (p=0.001), observing larger tumors and 
increased vascular invasion in patients carrying the wildtype. Furthermore, colon cancer 
patients with NOTCH2 rs11249433 T>C wildtype showed significantly increased 
lymphovascular invasion (p=0.001). No association was found between the other tested 
polymorphisms and clinicopathological features (data not shown).  
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The associations between all polymorphisms tested and TTR and OS are provided in Table 3. 
GLI1 rs2228226 G>C, AXIN2 rs3923086 T>G and AXIN2 rs4791171 A>G showed an 
association with TTR in a codominant model (p<0.05; Table 3). In multiple testing, only GLI1 
rs2228226 G>C using a recessive genetic model remained significant for TTR in univariate 
analysis (HR 2.35, Cl95% 1.48-3.74, p<0.001). Patients harbouring the homozygous mutant 
variant (C/C) had a median TTR of 52.2 months, in contrast to patients carrying the G/G or 
G/C genotype with a median TTR of 121.8 months (Figure 1). In OS analyses, no statistically 
significant association between the polymorphisms and OS could be found (Table 3). In the 
multivariate analysis including clinical stage (since clinical stage derives from tumor size and 
lymph node involvement, which all have been significant in univariate analysis, only clinical 
stage was incorporated in the multivariate model), lymphovascular-, vascular and 
perineural-invasion, the homozygous mutant variant of GLI1 rs2228226 G>C remained 
significantly associated with decreased TTR (HR 2.43, Cl95% 1.52-3.87, p<0.001).  
 
In interaction analysis, there was a significant association between GLI1 rs2228226 G>C and 
adjuvant chemotherapy with TTR (p<0.05). When only patients with surgery alone were 
analyzed, we found a highly significant association between GLI1 rs2228226 G>C and TTR 
(HR 3.21, Cl95% 1.59-6.49, p<0.001). Patients harbouring the homozygous mutant variant 
showed a median TTR of 49.9 months, while patients harbouring the G/G or G/C genotype 
had a median TTR of 123.6 months (Figure 2). In multivariate analysis including clinical stage, 
lymphovascular-, vascular- and perineural-invasion, we observed a statistical trend towards 
decreased TTR in patients carrying the homozygous mutant variant (HR 2.35; Cl95% 1.13-
4.850; p=0.022). In patients with adjuvant chemotherapy, we found no significant 
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association between GLI1 rs2228226 G>C and TTR (HR 1.99; Cl95% 1.06-3.72; p=0.031). In 
this subgroup, patients harbouring the C/C genotype had a median TTR of 52.5 months, in 
contrast to patients carrying the G/G or G/C genotype with a median TTR of 119.1 months 
(Figure 3).  
 
To evaluate if “high-risk” patients based on the GLI rs2228226 G>C polymorphism (40 
patients) benefit from adjuvant chemotherapy compared to surgery alone we performed a 
Kaplan-Meier analysis and log-rank test for this subgroup. According to the treatment 
regimen (surgery alone (19 patients) versus surgery plus adjuvant chemotherapy (21 
patients; 8 patients received 5-FU monotherapy, 7 patient capecitabine and 6 patients 
FOLFOX), no significant difference in TTR was identified in this high-risk subgroup (HR 0.82; 
Cl95% 0.35-1.95; p=0.657; Figure 4).    
 
When we correlated the GLI1 rs2228226 genotypes using the recessive genetic model with 
GLI1, IL17 and IL21 expression in tumor in a subset of patients (n=27 for wildtype and 
heterozygous mutant and n=12 for homozygous mutant) we found no significant association 
(p=0.697, p=0.338, p=0.596, respectively). 
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Discussion 
It is becoming increasingly apparent that disease progression and chemoresistance are 
driven by a multitude of signaling networks and the analysis of a single marker may fail to 
predict clinical outcome and treatment efficacy with a high degree of accuracy and 
reproducibility. Therefore, it is critical to adopt and implement a pathway-based approach. 
In the present study, we investigated germline polymorphisms in a comprehensive panel of 
Wnt, Notch and Hedgehog pathway genes to predict tumor recurrence in patients with stage 
II and III colon carcinoma. Our results indicate that GLI1 rs2228226 G>C may be an 
independent prognostic marker. Our findings further suggest that patients harbouring the 
homozygous mutant variant do not benefit from adjuvant 5-FU-based chemotherapy. 
 
The exact molecular mechanisms involved in how the GLI1 rs2228226 G>C polymorphism 
exerts effect on colon carcinoma outcome are not clarified yet. Non-synonymous 
polymorphisms result in amino acid changes and thus may affect the protein function (40).  
We used the F-SNP database to predict the functional effects of the analyzed 
polymorphisms. F-SNP gathers computationally predicted functional information about 
polymorphisms, particularly aiming to facilitate identification of disease-related 
polymorphisms in association studies (38, 39). When used for GLI1 rs2228226 G>C, F-SNP 
predicted changes in splicing regulation and post-translation, thus supporting the effects 
seen in our study. In a recent study, however, Paez et al investigated the association of GLI1 
rs2228226 with TTR in 234 patients with stage III and high-risk stage II patients, all treated 
with adjuvant 5-FU-based chemotherapy, but found no clinical effect (41). Moreover, in 
genome-wide association studies GLI1 rs2228226 has not been identified as a prognostic or 
predictive marker in colorectal cancer (42-44). 
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The Hedgehog signaling pathway induces expression of the gene SNAIL1, a transcription 
repressor of E-cadherin. Its transcriptional up-regulation is directly mediated by the 
transcription factor GLI1 (17). Patched 1 (PTCH1), a membrane protein, functions as a tumor 
suppressor and normally inhibits the membrane protein Smoothened (SMO) from activating 
GLI1. The binding of one of the three Hedgehog ligands (Sonic, Indian or Desert) to PTCH1 
abrogates its repressive effects on SMO allowing the translocation of GLI1 to the nucleus 
where it induces the expression of multiple target genes (45, 46). The Hedgehog signal 
transduction pathway regulates many processes of development and tissue homeostasis and 
is dysregulated in malignancies and inflammatory diseases of the gastrointestinal tract (47-
50).  
 
Increasing evidence supports the involvement of inflammation in cancer progression and 
metastasis (51, 52). Hedgehog signaling plays a crucial role in the inflammatory response 
since Sonic Hedgehog is critical for T lymphocyte development, adult human CD4+ T cell 
activation and myeloid cell maturation (53-56). Recently, Lees et al demonstrated an overall 
down-regulation of Hedgehog signalling pathway activity, including GLI1 and PTCH, in colonic 
inflammation in humans. Furthermore, they identified the GLI rs2228226 G>C polymorphism 
as functionally deficient in activating GLI-responsive transcription in vitro, showing a 50% 
less efficient transcriptional activity compared to the wildtype (57). GLI1 rs2228226 G>C 
encodes a change from glutamine to glutamic acid, causing a significant charge change in a 
conserved region adjacent to the known transactivation region of GLI1, that may directly 
modify transactivation activity and/ or affect protein stabilization (58). In addition, Lees et al 
showed in an established mouse model of colitis that animals carrying the mutant allele of 
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GLI1 rs2228226 G>C develop severe intestinal inflammation, indicating that tolerance to 
inflammatory stimuli requires a fully functional Hedgehog signal transduction network (51). 
The most highly expressed cytokine in mice harbouring the mutant allele of GLI1 rs2228226 
G>C in their study was IL-23, a molecule that promotes the differentiation of T-helper IL-17-
producing (TH17) cells that are involved in inflammation processes, including inflammatory 
bowel disease (57). IL-23 is also known as a pro-carcinogenic cytokine, which is mainly 
produced by tumor-associated macrophages in the tumor microenvironment, via direct 
transcriptional activation of the IL-23/p19 gene (59). In the study by Lees at al, also IL-17, a 
cytokine closely associated with IL-23, was markedly up-regulated in animals harbouring the 
GLI1 rs2228226 G>C mutant variant (57). Grivennikov et al investigated mechanisms 
responsible for tumor-elicited inflammation in a mouse model of colorectal carcinogenesis, 
which, like human colorectal carcinoma, also exhibited up-regulation of IL-23 and IL-17 (59). 
They found that IL-23 signaling promotes tumor growth and progression, and the 
development of tumoral IL-17 response, resulting in an additional aggravation of disease 
progression (60). Efforts to target pathogenic Hedgehog signaling have steadily progressed 
from the laboratory to the clinic, and the recent approval of vismodegib for patients with 
advanced basal cell carcinoma represents an important milestone (61-66). However, in a 
recent phase II study, vismodegib did not add to the efficacy of standard first-line treatment 
for metastatic colorectal cancer (67).   
 
In our study cohort, we found a statistically significant association between GLI1 rs2228226 
G>C and TTR, showing a decreased TTR in patients carrying the homozygous mutant 
genotype. Hence, we hypothesize that colon carcinoma patients harbouring the functionally 
deficient homozygous mutant variant, which is associated with up-regulation of IL-23 and IL-
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17 are more likely to develop a recurrent disease, due to a supportive inflammatory 
microenvironment for tumor growth. However, we could not experimentally underline this 
biological function since the GLI1 rs2228226 genotypes were not significantly associated 
with GLI1, IL17 and IL21 expression in tumor in a subset of our patient cohort. Our results 
further suggest that patients harbouring the homozygous mutant variant of GLI1 rs2228226 
G>C do not benefit from adjuvant 5-FU-based chemotherapy. We also found a significant 
association between APC rs454886 G/G and larger tumor size and increased vascular 
invasion, furthermore, patients with NOTCH2 rs11249433 TT showed an increased 
lymphovascular invasion. F-SNP predicted changes in the transcriptional regulation for the 
intronic APC rs454886 G>A. No prediction could be provided for the intergenic located 
NOTCH2 rs11249433 T>C by the software (38, 39). Since the biological function of these 
SNPs is unknown, these associations remain to be elucidated.  
 
The strength of the present study is the large sample size and the long follow-up period. 
However, because of the retrospective study design a selection bias cannot be fully 
excluded. The subgroup of “high-risk” GLI1 rs2228226 C/C included overall only 40 patients 
and only 21 patients treated with various chemotherapy regimens. Therefore, it is currently 
unknown if this association is truly significant and/ or if only patients with monotherapy or 
both, mono- and combination therapy do not benefit in this “high-risk” subgroup. Another 
limitation is the lack of the MSI-status in our study cohort, hence the evaluation of GLI1 
rs2228226 G>C in comparison to MSI was not feasible. Finally, the method of preservation of 
the tissue samples was performed by 3 different institutions over a number of years, 
undermining the consistency of sample preparation.  
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In conclusion, this study provides the first evidence that GLI1 rs2228226 G>C may predict 
early tumor recurrence in stage II and III colon carcinoma patients. Prospective studies are 
warranted to validate our findings. 
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Figure Legends 
Figure 1 
Association between GLI1 rs2228226 G>C and TTR in all colon carcinoma patients 
TTR, time to recurrence  
Figure 2 
Association between GLI1 rs2228226 G>C and TTR in colon carcinoma patients with surgery 
alone 
TTR, time to recurrence 
Figure 3 
Association between GLI1 rs2228226 G>C and TTR in colon carcinoma patients with adjuvant 
chemotherapy 
TTR, time to recurrence 
Figure 4 
Association in colon carcinoma patients homozygous mutant (C/C) for GLI1 rs2228226 G>C 
(40 patients) between adjuvant chemotherapy (21 patients) or surgery alone (19 patients) 
and TTR 
TTR, time to recurrence 
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Table 1 
Analyzed Wnt/ Notch/ Hedgehog pathway genes and polymorphisms 
Pathway Gene Function rs-number Base exchange Location Association
WNT SFRP Soluble Wnt 
receptor 
rs1802073 C>A Non-
synonymous 
Rectal cancer 
risk (26)  
WNT SFRP Soluble Wnt 
receptor 
rs288326 G>A Non-
synonymous 
CRC risk (21, 
22)  
WNT SFRP Soluble Wnt 
receptor 
rs7775 C>G Non-
synonymous 
CRC risk (21, 
22) 
WNT DKK2 Inhibits Wnt 
by binding to 
LRP5/6 
rs17037102 G>A Non-
synonymous 
RCC outcome 
(20) 
WNT DKK3 Inhibits Wnt 
by binding to 
LRP5/6 
rs3206824 A>G Non-
synonymous 
RCC risk (20)
WNT DKK3 Inhibits Wnt 
by binding to 
LRP5/6 
rs1472189 C>T 3 UTR RCC outcome 
(20) 
WNT DKK3 Inhibits Wnt 
by binding to 
LRP5/6 
rs7396187 C>G Intron  RCC risk (20)
WNT AXIN2 Suppressor rs11079571 A>G Intron BC risk (23)
WNT AXIN2 Suppressor rs4791171 A>G Intron BC risk (23)
WNT AXIN2 Suppressor rs3923086 T>G Intron BC risk (23)
WNT AXIN2 Suppressor rs3923087 A>G Intron BC risk (23)
WNT APC Suppressor rs454886 T>C Intron BC risk (23)
WNT AXIN2 Suppressor rs2240308 G>A Non-
synonymous  
NSCLC risk (24)
WNT MYC Wnt 
enhancer 
rs6983267 G>T 8q24, non-
coding, near 
MYC  
CRC risk (27)
WNT TCF7L2 Transcription 
factor 
activator 
rs12255372 G>T Intron CRC risk (25)
WNT TCF7L2 Transcription 
factor 
rs7903146 C>T Intron CRC risk (28)
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activator 
NOTCH NOTCH2 NOTCH 
receptor 
rs11249433 T>C 1p11.2, 
within non-
coding gene 
BC (29)
HEDGEHOG GLI1 transcription
al activator 
rs2228226 G>C Non-
synonymous 
IBD risk (47)
 
CRC, colorectal cancer; RCC, renal cell cancer; BC, breast cancer; NSCLC, non small cell lung 
cancer; IBD, inflammatory bowel disease; NA, not available 
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Table 2 
Clinicopathological characteristics and TTR and OS in univariate analysis 
Parameter N % TTR OS 
   HR (95%CI) p-value HR (95%CI) p-value 
Gender 
 Male 
 Female 
 
416 
326 
 
56.1 
43.9 
 
1 (reference) 
0.96 (0.74-1.24) 
 
0.750 
 
1 (reference) 
0.89 (0.67-1.17) 
 
0.401 
Tumor location 
 Left 
 Right 
 
274 
468 
 
36.9 
63.1 
 
1 (reference) 
0.83 (0.64-1.08) 
 
0.168 
 
1 (reference) 
0.73 (0.55-0.96) 
 
0.025 
Tumor size 
 T1 
 T2 
 T3 
 T4 
 
12 
32 
536 
162 
 
1.6 
4.3 
72.2 
21.8 
 
1 (reference) 
0.97 (0.10-9.35) 
3.27 (0.46-23.36) 
6.58 (0.91-47.35) 
 
 
<0.001 
 
 
1 (reference) 
1.33 (0.16-11.43) 
2.26 (0.32-16.15) 
5.56 (0.77-40.05) 
 
 
<0.001 
 
Lymph node involvement 
 N0 
 N1 
 N2 
Unknown 
 
298 
276 
167 
1 
 
40.2 
37.2 
22.5 
0.1 
 
1 (reference) 
1.44 (1.03-2.02) 
3.86 (2.80-5.32) 
 
 
<0.001 
 
1 (reference) 
1.33 (0.93-1.88) 
3.12 (2.23-4.36) 
 
 
<0.001 
 
Tumor grade 
 G1 
 G2 
 G3 
Unknown 
 
37 
480 
224 
1 
 
5 
64.7 
30.2 
0.1 
 
1 (reference) 
1.16 (0.57-2.37) 
1.40 (0.68-2.91) 
 
 
0.337 
 
1 (reference) 
0.77 (0.37-1.57) 
1.12 (0.54-2.33) 
 
 
0.032 
 
Lymphovascular invasion 
No 
Yes 
 
532 
210 
 
71.7 
28.3 
1 (reference) 
1.58 (1.21-2.06) 
0.001 
 
1 (reference) 
1.47 (1.10-1.96) 
0.009 
Vascular invasion 
No 
Yes 
 
665 
77 
 
89.6 
10.4 
1 (reference) 
2.40 (1.73-3.32) 
<0.001 
 
1 (reference) 
2.06 (1.43-2.96) 
0.001 
Perineural invasion 
No  
Yes 
 
721 
21 
 
97.2 
2.8 
 
1 (reference) 
3.64 (2.12-6.26) 
 
<0.001 
 
1 (reference) 
2.45 (1.29-4.62) 
 
0.006 
 Clinical stage 
 II 
 III 
Unknown 
 
295 
446 
1 
 
39.8 
60.1 
0.1 
 
1 (reference) 
2.26 (1.69-3.03) 
 
<0.001 
 
1 (reference) 
1.92 (1.42-2.58) 
 
<0.001 
 Adjuvant chemotherapy 
 No 
 Yes 
Unknown 
 
256 
483 
3 
34.5 
65.1 
0.4 
1 (reference) 
1.18 (0.90-1.56) 
0.239 
 
1 (reference) 
0.86 (0.65-1.14) 
0.300 
 
TTR, time to recurrence; OS, overall survival 
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Table 3 
Association between the polymorphisms and TTR and OS in univariate analysis 
Polymorphism N TTR  OS  
  HR (95%CI) p-value HR (95%CI) p-value 
SFRP rs1802073 
 C/C 
 C/A 
 A/A 
 
217 
231 
63 
 
 
0.98 (0.78-1.23) 
 
 
 
0.858 
 
 
0.93 (0.72-1.19) 
 
 
 
0.568 
SFRP rs288326 
 G/G 
 G/A 
 A/A 
 
7 
103 
363 
 
 
1.04 (0.74-1.48) 
 
 
 
0.809 
 
 
0.78 (0.55-1.10) 
 
 
 
0.156 
SFRP rs7775 
 C/C 
 C/G 
 G/G 
 
6 
64 
436 
 
 
1.01 (0.66-1.54) 
 
 
 
0.967 
 
 
 
1.04 (0.65-1.68) 
 
 
 
0.866 
 
DKK2 rs17037102  
 G/G 
 G/A 
 A/A 
 
408 
88 
4 
 
 
0.83 (0.56-1.23) 
 
 
 
0.351 
 
 
0.89 (0.58-1.37) 
 
 
 
0.586 
 
DKK2 rs3206824 
 A/A 
 A/G 
 G/G 
 
288 
188 
34 
 
 
1.01 (0.79-1.30) 
 
 
 
0.922 
 
 
1.05 (0.80-1.37) 
 
 
 
0.745 
 
DKK2 rs1472189 
C/C 
C/T 
T/T 
 
241 
220 
50 
 
 
0.90 (0.71-1.15) 
 
 
0.405 
 
 
1.11 (0.85-1.44) 
 
 
0.438 
DKK2 rs7396187  
C/C 
C/G 
G/G 
 
14 
156 
283 
 
1.19 (0.87-1.63) 
 
0.285 
 
 
0.91 (0.66-1.26) 
 
0.575 
AXIN2 rs11079571 
A/A 
A/G 
G/G 
 
22 
189 
283 
 
 
1.23 (0.92-1.64) 
 
0.171 
 
 
1.08 (0.79-1.48) 
 
0.645 
 AXIN2 rs4791171 
A/A 
A/G 
G/G 
 
205 
251 
52 
 
0.72 (0.56-0.93) 
 
0.012 
 
 
0.80 (0.60-1.05) 
 
0.108 
AXIN2 rs3923086 
T/T 
T/G 
G/G 
 
107 
261 
142 
 
 
1.31 (1.05-1.65) 
 
 
0.019 
 
 
1.19 (0.93-1.52) 
 
 
0.160 
AXIN2 rs3923087 
A/A 
A/G 
G/G 
 
255 
210 
32 
 
0.78 (0.60-1.02) 
 
0.073 
 
 
0.85 (0.63-1.14) 
 
0.270 
APC rs454886      
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T/T 
T/C 
C/C 
267 
201 
30 
0.76 (0.60-1.01) 0.054 
 
0.79 (0.58-1.07) 0.121 
AXIN2 rs2240308 
G/G 
G/A 
A/A 
 
114 
267 
129 
 
 
0.80 (0.64-1.00) 
 
 
0.054 
 
 
0.90 (0.71-1.15) 
 
 
0.407 
Near MYC rs6983267 
G/G 
G/T 
T/T 
 
112 
252 
112 
 
 
0.85 (0.66-1.08) 
 
 
0.189 
 
 
0.95 (0.73-1.24) 
 
 
0.719 
TCF7L2 rs12255372 
G/G 
G/T 
T/T 
 
252 
199 
40 
 
1.09 (0.85-1.40) 
 
0.485 
 
 
0.10 (0.76-1.31) 
 
0.974 
TCF7L2 rs7903146 
C/C 
C/T 
T/T 
 
248 
205 
43 
 
 
1.06 (0.83-1.36) 
 
 
0.649 
 
 
0.93 (0.71-1.22) 
 
 
0.601 
NOTCH2 rs11249433 
T/T 
T/C 
C/C 
 
176 
244 
85 
 
0.96 (0.77-1.19) 
 
0.682 
 
 
1.05 (0.83-1.33) 
 
0.696 
GLI1 rs2228226 
G/G 
G/C 
C/C 
 
249 
209 
40 
 
 
1.36 (1.06-1.74) 
 
 
 
0.015 
 
 
1.22 (0.93-1.61) 
 
 
0.156 
 
TTR, time to recurrence; OS, overall survival 
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